PTC Therapeutics, Inc.
PTCT
$40.64
-$2.18-5.09%
| Weiss Ratings | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Good | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.10 | |||
| Price History | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -25.11% | |||
| 30-Day Total Return | -19.34% | |||
| 60-Day Total Return | -7.56% | |||
| 90-Day Total Return | -5.51% | |||
| Year to Date Total Return | -11.46% | |||
| 1-Year Total Return | 51.12% | |||
| 2-Year Total Return | -16.47% | |||
| 3-Year Total Return | -5.20% | |||
| 5-Year Total Return | -8.00% | |||
| 52-Week High % Change | -26.65% | |||
| 52-Week Low % Change | 78.45% | |||
| Price | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $58.38 | |||
| 52-Week Low Price | $24.00 | |||
| 52-Week Low Price (Date) | Apr 25, 2024 | |||
| 52-Week High Price (Date) | Mar 17, 2025 | |||
| Valuation | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.38B | |||
| Enterprise Value | 4.69B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -4.73 | |||
| Earnings Per Share Growth | -43.52% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 4.10 | |||
| Price/Book (Q) | -3.03 | |||
| Enterprise Value/Revenue (TTM) | 5.82 | |||
| Price | $40.62 | |||
| Enterprise Value/EBITDA (TTM) | -66.05 | |||
| Enterprise Value/EBIT | -31.99 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 77.20M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 908 222 7000 | |||
| Address | 500 Warren Corporate Center Drive Warren, NJ 07059 | |||
| Website | www.ptcbio.com | |||
| Country | United States | |||
| Year Founded | 1998 | |||
| Profitability | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -18.18% | |||
| Profit Margin | -45.03% | |||
| Management Effectiveness | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -5.09% | |||
| Return on Equity | -- | |||
| Income Statement | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 806.78M | |||
| Total Revenue (TTM) | 806.78M | |||
| Revenue Per Share | $10.45 | |||
| Gross Profit (TTM) | 214.90M | |||
| EBITDA (TTM) | -71.08M | |||
| EBIT (TTM) | -146.75M | |||
| Net Income (TTM) | -363.30M | |||
| Net Income Avl. to Common (TTM) | -363.30M | |||
| Total Revenue Growth (Q YOY) | -30.58% | |||
| Earnings Growth (Q YOY) | 57.71% | |||
| EPS Diluted (TTM) | -4.73 | |||
| EPS Diluted Growth (Q YOY) | 58.65% | |||
| Balance Sheet | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.15B | |||
| Cash Per Share (Q) | $14.94 | |||
| Total Current Assets (Q) | 1.37B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -1.10B | |||
| Current Ratio (Q) | 2.350 | |||
| Book Value Per Share (Q) | -$14.13 | |||
| Total Assets (Q) | 1.71B | |||
| Total Current Liabilities (Q) | 580.98M | |||
| Total Debt (Q) | 2.47B | |||
| Total Liabilities (Q) | 2.80B | |||
| Total Common Equity (Q) | -1.10B | |||
| Cash Flow | PTCT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 44.18M | |||
| Cash from Financing (TTM) | 255.87M | |||
| Net Change in Cash (TTM) | 185.03M | |||
| Levered Free Cash Flow (TTM) | -80.97M | |||
| Cash from Operations (TTM) | -107.69M | |||
